Aug 20 (Reuters) - Valeant Pharmaceuticals International Inc (NYSE:VRX) VRX.TO :
* To acquire sprout pharmaceuticals
* Says deal valued at about C$1 billion
* Says addyi expected to launch in U.S. in the fourth quarter of 2015
* Says expects addyi to be available in the United States in the fourth quarter
of 2015
* Says Valeant will leverage its global scale to register flibanserin
internationally
* Following closing of the acquisition, sprout will remain headquartered in
Raleigh, n.c. and become a division of Valeant
* Says Valeant expects no impact to 2015 earnings, and moderate accretion to
2016 earnings
* Will acquire sprout, on a debt-free basis; deal includes share of future
profits based on milestones
* Cindy Whitehead, chief executive officer of sprout, will join Valeant to lead
division dedicated to addyi
* Says Valeant will pay approximately $500 million, subject to customary
purchase price adjustments
* Unit to buy sprout, on a debt-free basis, for $1 billion in cash, plus a
share of future profits based upon achievement of some milestones
* Upon closing of deal, to pay additional $500 million, payable in Q1 of 2016,
plus a share of future profits
* Source text for Eikon ID:nCNWMLbGfa
* Further company coverage VRX.TO